Physician profile
Mark Werner
NPI 1609849561
$5,295.67
in general payments reported to CMS, 2019-2025
36 companies · $438 in 2025
The $438 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $401 · 2021: $1,241 · 2022: $1,341 · 2023: $840 · 2024: $587 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.66 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $1,178.34 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $791.05 | 2019-2025 | Contrave, Nexletol, Nexlizet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $668.07 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $355.84 | 2023-2025 | Myfembree |
| Abbvie INC. | $298.79 | 2019-2022 | |
| Novo Nordisk INC | $270.60 | 2019-2025 | Wegovy, Saxenda |
| Pfizer INC. | $187.18 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $178.33 | 2022 | |
| Daiichi Sankyo INC. | $177.77 | 2020-2021 | |
| Lilly USA, LLC | $147.10 | 2021-2025 | Zepbound, Mounjaro |
| Bausch Health US, LLC | $129.78 | 2019-2022 | |
| Astellas Pharma US INC | $125.87 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $101.97 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Otsuka America Pharmaceutical, INC. | $86.45 | 2023-2024 | Rexulti |
| Aspira Women'S Health INC | $61.14 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.59 | 2021-2022 | |
| Scynexis, INC. | $44.89 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $44.02 | 2019 | |
| Avion Pharmaceuticals | $39.16 | 2019-2020 | |
| Allergan, INC. | $36.62 | 2019 | |
| Coopersurgical, INC. | $29.27 | 2020-2022 | |
| Therapeuticsmd, INC. | $27.79 | 2019 | |
| Phathom Pharmaceuticals, INC. | $27.59 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $25.49 | 2021 | |
| Sage Therapeutics, LLC | $24.86 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $24.28 | 2023 | Quviviq |
| Mayne Pharma Commercial LLC | $20.76 | 2023 | |
| Mycovia Pharmaceuticals, INC. | $19.25 | 2023 | Vivjoa |
| Convatec INC. | $18.80 | 2022 | |
| Organon LLC | $17.65 | 2023 | Nexplanon |
| Medicem INC. | $16.63 | 2023 | |
| Supernus Pharmaceuticals, INC. | $16.24 | 2022 | |
| Exact Sciences Corporation | $16.13 | 2024 | Cologuard Collection Kit |
| Gynesonics, INC. | $15.35 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Millicent US INC | $13.67 | 2024 | Intrarosa |
| Exeltis, USA INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.